Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options begin trading today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day ... Elsewhere, the Dow gained 0.91%, while the tech-heavy Nasdaq added 1.35%. The the stock of drugmaker has fallen by 12.22% ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session ... Meanwhile, the Dow experienced a drop of 0.25%, and the technology-dominated Nasdaq saw an increase of 1.24%.

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

In trading on Thursday, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) entered into oversold territory, hitting an RSI reading of 24.8, after changing hands as low as $377.85 per share.

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Low PE Investor model based on the published ...

Fintel reports that on December 9, 2024, Jefferies upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Hold to Buy. As of December 2, 2024, the average one-year price target for ...

Regarding VRTX (NASDAQ:VRTX), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on January 17, 2025. Parties traded 25 contract(s) at a $410.00 strike. This particular ...

Fintel reports that on December 9, 2024, Jefferies upgraded their outlook for Vertex Pharmaceuticals (WBAG:VRTX) from Hold to Buy. There are 2,805 funds or institutions reporting positions in ...

Vertex Pharmaceuticals (VRTX) closed at $469.29 in the latest trading ... Elsewhere, the Dow lost 0.35%, while the tech-heavy Nasdaq lost 0.25%. Shares of the drugmaker witnessed a loss of 5. ...

It has been about a month since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have lost about 8.6% in that time frame, underperforming the S&P 500. Will the recent negative ...

Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...